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Pterygium syndromes are complex congenital disorders that encompass several distinct clinical conditions characterized by multiple
skin webs affecting the flexural surfaces often accompanied by craniofacial anomalies. In severe forms, such as in the autosomal-reces-
sive Bartsocas-Papas syndrome, early lethality is common, complicating the identification of causative mutations. Using exome
sequencing in a consanguineous family, we identified the homozygous mutation c.1127C>A in exon 7 of RIPK4 that resulted in the
introduction of the nonsense mutation p.Ser376X into the encoded ankyrin repeat-containing kinase, a protein that is essential for ker-
atinocyte differentiation. Subsequently, we identified a second mutation in exon 2 of RIPK4 (c.242T>A) that resulted in the missense
variant p.Ile81Asn in the kinase domain of the protein. We have further demonstrated that RIPK4 is a direct transcriptional target of
the protein p63, a master regulator of stratified epithelial development, which acts as a nodal point in the cascade of molecular events
that prevent pterygium syndromes.The epidermis is a highly organized, stratified, self-renew-
ing epithelium that functions as a barrier to protect the
organism from dehydration, mechanical trauma, and
microbial invasion.1,2 During development, the immature
ectoderm initially consists of a single layer of mitotically
active, undifferentiated, cuboidal epithelial cells that
progress through a defined series of stratification and
differentiation events to produce the mature epidermis
that consists of four distinct cellular layers maintained
by a constant process of displacement and renewal. Devel-
opment and subsequent maintenance of the epidermis
are therefore critically dependent on the intricate balance
between proliferation and differentiation of a mitotically-
active basal cell population.1,2 Disruption of this balance
results in a wide variety of congenital anomalies of
epidermal development that have profound effects on
affected individuals and their families.
Pterygium syndromes are complex, congenital disorders
that include several different clinical conditions character-
ized by multiple skin webs affecting the flexural surfaces
and associated craniofacial anomalies. To date, Van der
Woude syndrome (MIM 119300) and popliteal pterygium
syndrome (MIM 119500) have been demonstrated to result
from mutations in the transcription factor IRF6 (MIM
607199),3 whereas mutation of the gene encoding the
NF-kB pathway component IkB kinase-a (IKKA [MIM
600664]) underlies an autosomal-recessive lethal syndrome
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The Amsyndrome (MIM 613630).4 Despite these advances, the
molecular basis of other pterygium syndromes remains
elusive. Bartsocas-Papas syndrome (MIM 263650) is a
devastating autosomal-recessive disorder characterized
by multiple popliteal pterygia, ankyloblepharon, filiform
bands between the jaws, cleft lip and palate, and syndac-
tyly.5 Early lethality is common, though survival into
childhood and beyond has been reported.5
To determine the molecular basis of Bartsocas-Papas
syndrome, we performed exome sequencing on a single
individual affected by this condition. The proband was
the second child of consanguineous parents; no other
significant previous family history was identified. Routine
anomaly scanning during pregnancy revealed multiple
congenital abnormalities. Further investigation during
pregnancy was declined. Fetal bradycardia was noted on
monitoring 1 week preterm, and an elective Cesarean
section was performed. Birth weight was 2.95 kg and the
occipitofrontal circumference was 34 cm. Multiple con-
genital abnormalities, including alopecia totalis with
only sparse scalp hair, partial ankyloblepharon, oral
synechia resulting in partial occlusion of the oral cavity,
hypertelorism, cloudy corneas, absent thumbs, finger
oligosyndactyly, hypoplastic genitalia, extensive popliteal
pterygia, toe oligosyndactyly, multiple skin tags, and
unusual fibrous tethers between the feet and suprapubic
region were noted (Figures 1A and 1B). On the basis of
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Figure 1. Homozygous Mutations in RIPK4
Underlie Bartsocas-Papas Syndrome
(A and B) Clinical pictures of the affected child
whose DNA was subject to exome sequencing.
The alopecia, partial ankyloblepharon, oral
synechia resulting in partial occlusion of the
oral cavity, oligosyndactyly, popliteal pterygia,
and fibrous tethers between feet and suprapubic
region are apparent.
(C) Partial pedigree of the family. The shaded
symbol represents the affected child.
(D) Sequencechromatogramsshowingsegregation
of the homozygous NM_020639.2:c.1127C>A
mutation, which resulted in the nonsense change
p.S376X and the affected phenotype.
(E) Sequence chromatogram of the homozygous
NM_020639.2:c.242T>A mutation, which re-
sulted in the missense change p.Ile81Asn.
(F) RIPK4 expression in E18.5 mouse epidermis.
Cytoplasmic immunofluorescence (red) is ob-
served in basal and suprabasal layers with
the nuclei counterstained with DAPI (blue).
The dotted line indicates the position of the
basement membrane. The scale bar represents
25 mm.syndrome was made. The patient is alive at 6 years of age
and intellectual development appears normal. DNA
samples were obtained from three members of the family
(Figure 1C) via standard procedures and with informed
consent under the relevant institutional review boards
and the UK National Research Ethics Service.
Targeted enrichment and sequencing were performed
on 3 mg of DNA extracted from peripheral blood of
the affected child. Enrichment was performed with the
SureSelect Human All Exon 50 MB Kit (Agilent, Santa
Clara, CA, USA) for the ABI SOLiD system following the
manufacturer’s protocols. ePCR was conducted on the
resulting sample library that was then sequenced and in-
dexed with two unrelated samples, on a SOLiD 4 sequencer
(Life Technologies, Carlsbad, CA, USA) following the
manufacturer’s protocols.
Sequence data were mapped with SOLiD Bioscope soft-
ware (Life Technologies) and hg19 human genome as
a reference. An average of 5.92 gigabases of sequence map-
ped uniquely to the human genome; 71.3% of the targeted
exome had coverage at 20-fold or higher. Variants were
called with a combination of the diBayes tool in the Bio-
scope software suite with the medium stringency and
Samtools and then filtered for those SNPs with 5-fold or
greater coverage. SNPs were initially annotated using
Ensembl v61 and Ensembl’s defined consequence hierar-
chically system, the highest impacting consequence for
a variant in a gene being retained. Variants were filtered70 The American Journal of Human Genetics 90, 69–75, January 13, 2012out if they were nonfunctional in
dbSNP132 (unless seen in the Human
Gene Mutation Database) or in our in-
house variant database. At the time of the
comparison, the latter database consisted
of 23 exomes. For the recessive-mutationmodel, homozygous variants were filtered, and there was
a further 20-fold filtering at novel allele depth and
a mapping quality value of 20.
Among the 75 unique homozygous sequence variants
identified across the exome of the child affected with
Bartsocas-Papas syndrome, a C>A transversion was
noted in exon 7 of RIPK4 (MIM 605706) (genomic
DNA: chromosome 21[NCBI 36]:g.43164110; cDNA:
NM_020639.2:c.1127C>A), which resulted in the homo-
zygous nonsense mutation p.Ser376X (Figure 1D and
Figure S1, available online). This variant lies in a 9.3 MB
region of homozygosity between rs1053808 and
rs1044998. Sanger sequencing confirmed that the parents
were heterozygous for the mutation (Figure 1D). In light
of these findings, we used Sanger sequencing to analyze
a DNA sample from an additional unrelated affected
individual who has been reported previously6 and identi-
fied a homozygous T>A transversion in exon 2 of RIPK4
(genomic DNA: chromosome 17[NCBI 36]:g.43176917;
cDNA: NM_020639.2:c.242T>A), which resulted in the
homozygous missense change p.Ile81Asn in the kinase
domain of the protein (Figure 1E).7 Although DNA samples
from the parents are not available, bioinformatics analysis
confirmed that neither of these mutations was present
in either dbSNP, the 1000 Genomes Database, or in over
4,000 chromosomes for the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project with
over 203 coverage. Moreover, the isoleucine amino acid
residue at position 81 is completely conserved in
mammals, fish, chickens, and frogs (Figure S2).
To provide further support for RIPK4 mutations under-
lying the Bartsocas-Papas syndrome phenotype, we per-
formed immunolocalization studies of neonatal mouse
epidermis. Following dissection and fixation, samples
were dehydrated through a graded ethanol series, cleared
in chloroform, embedded in paraffin wax, and sectioned.
Immunofluorescence analysis was performed with an anti-
body raised against RIPK4 (Abcam, Cambridge, UK). The
primary antibody was detected with an Alexafluor 488-
conjugated secondary antibody (Invitrogen, Grand Island,
NY, USA) and mounted in fluorescence mountant contain-
ing 4’,6-diamidino-2-phenylindole ([DAPI] Vector Labora-
tories, Burlingame, CA, USA). Sections were examined
with a Digital Module RB (DMRB) microscope (Leica)
with a Spot digital camera and associated software (RTKE/
SE, Diagnostic Instruments, Sterling Heights, MI, USA).
In agreement with previous reports that used mouse tail
skin that closely resembles the multilayered human
epidermis,8 RIPK4 immunoreactivity was detected in the
cytoplasm of the basal and suprabasal epidermal keratino-
cytes (Figure 1F).
Previous results have demonstrated that RIPK4 plays
a key role in controlling keratinocyte differentiation,8–11
Ripk4-null mice exhibiting severe epidermal adhesions
that phenocopy Bartsocas-Papas syndrome.9 A highly
similar phenotype is also observed in mice carrying loss-
of-function mutations in either the transcription factor
Interferon Regulatory Factor 6 (Irf6), the NF-kB pathway
component IkB kinase-a (Ikka), or the cell-cycle regulator
protein stratifin (Sfn),12–19 proteins that are under the
direct control of the transcription factor p63.20–23 TP63
(MIM 603273) encodes at least six protein variants result-
ing from the usage of two different transcription start sites
and alternative splicing. Although all isoforms contain
a DNA binding domain, different promoters give rise to
two alternative N termini; TA isoforms that contain a trans-
activation sequence andDN isoforms that contain a shorter
activation domain.24,25 Alternative splicing toward the
carboxy terminus generates three subtypes; a, b, and g.25
DNp63a is the major isoform expressed in basal epithelial
cells24,26–28 and is essential for epidermal development
with mutations in TP63 resulting in a series of develop-
mental disorders characterized by varying combinations
of ectodermal dysplasia, facial clefting, and limb abnor-
malities including ectrodactyly-ectodermal dysplasia-cleft-
ing syndrome (MIM 604292) and ankyloblepharon-ecto-
dermal dysplasia-clefting syndrome (MIM 106260).26,29
Although these features are partially recapitulated in
Trp63 mutant mice that exhibit truncations of the limbs
and craniofacial anomalies, the epidermis of Trp63-null
mice is thin, fails to stratify, and lacks ectodermal append-
ages such as hairs, whiskers, teeth, and several glands,
including mammary, salivary, and lacrimal glands.30,31
As p63 is required for development and maintenance of
epidermal keratinocytes,32 we tested whether RIPK4 is aThe Amdirect transcriptional target of p63 by analyzing a
genome-wide p63 binding profile in human primary
keratinocytes generated with ChIP-seq analysis.33We iden-
tified four high-fidelity peaks within 56 kb of the RIPK4
transcription start site; two peaks resided upstream of
RIPK4 (þ16.5 kb and þ11 kb), one peak resided in RIPK4
intron 2 (15 kb), and the final peak was located down-
stream of the gene (39 kb). All four peaks fell in conserved
regions of the genome (Figure 2A and Figure S3). In
addition, all four regions were strongly enriched for
monomethylated histone H3 lysine 4, dimethylated
histone H3 lysine 4, acetylated histone H3 lysine 9, and
acetylated histone H3 lysine 27 in normal human
epidermal keratinocytes (Figure 2A), chromatin signatures
that mark sites of enhancer activity.34,35 The p53scan
algorithm, which is suitable for binding motif searches
for p53 family members,36 identified consensus binding
motifs in all four binding sites; however, only binding sites
3 and 4 were conserved in the mouse (Figure S3).
To confirm the p63 binding sites identified in ChIP-seq
analysis, we performed independent ChIP-qPCR experi-
ments. Human HaCaT cells were crosslinked with 1%
formaldehyde for 10 min, and chromatin was collected
as described previously.37 Chromatin was sonicated with
a Vibracell sonicator (Sonics, Newtown, CT, USA) for eight
pulses, each of 10 s, at an amplitude setting of 40 and
precipitated with the H129 antibody (SC-8344; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) raised against
the a-tail of p63 (amino acids 513–641). ChIP efficiencies
expressed as a percentage of total chromatin confirmed
enrichment from HaCaT cells at all four peaks compared
to the myoglobin negative control (p ¼ 0.0079 Mann-
Whitney U; Figure 2B). As enhancer elements have been
shown to exhibit tissue- and species-specific activities,38
we performed ChIP-qPCR on epidermis dissected from
embryonic day (E)18.5 wild-type mice and, in agreement
with the conservation data (Figure S3), demonstrated
that enrichment was achieved at binding sites 3 and 4
(Figure 2C). ChIP-qPCR further demonstrated that binding
site 3, but not binding site 4, was enriched in chromatin
precipitated from facial processes dissected from E11.5
mouse embryos (Figure S4).
p63 can act as either an activator or a repressor depend-
ing on the target gene.39,40 To investigate the specific
effects of p63 on RIPK4 transcription, the genomic regions
encompassing the four p63 binding sites identified in
human keratinocytes were amplified by PCR (Table S2)
and cloned into a firefly luciferase reporter gene. Two
hundred nanograms each of the firefly luciferase reporter,
the Renilla luciferase control pRL-CMV, and a DNp63a
wild-type expression plasmid that has been described
previously27 were transfected into Sarcoma osteogenic
cell line (SAOS2) cells for 24 hr with Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen).
The cells were then lysed and luciferase activity measured
with a dual luciferase reporter assay according to the
manufacturer’s instructions (Promega). All transfectionserican Journal of Human Genetics 90, 69–75, January 13, 2012 71
Figure 2. p63 Binds in to Genomic Regions in Close Proximity to RIPK4
(A) The position of the four p63 binding regions (BS-1, BS-2, BS-3, and BS-4) around RIPK4 previously identified by ChIP-seq analysis
of human primary keratinocytes with the p63 antibodies 4A4 and H129 (blue peaks)33 correlate with highly conserved regions of
the genome that are enriched for regulatory marks in normal human epidermal keratinocytes (NHEK) that are strongly associated
with enhancer regions. The following abbreviations are used: H3K4me1,monomethylated histone H3 lysine 4; H3K4me2 dimethylated
histone H3 lysine 4; H3K9 ac, acetylated histone H3 lysine 9; H3K27 ac, acetylated histone H3 lysine 27.
(B) ChIP-qPCR analysis using the p63 antibody H129 in human HaCaT cells confirms specific binding of p63 to all four binding sites
but not to the negative control myoglobin exon 2 (Control [Ctr]) (*p ¼ 0.0079).
(C) ChIP-qPCR analysis using the p63 antibody H129 confirms specific binding of p63 to the conserved binding sites BS-3 and BS-4
but not to the negative control myoglobin exon 2 (Ctr) in E18.5 mouse epidermis (*p ¼ 0.03 Mann; Whitney U test).
The error bars in B and C indicate standard error of the mean.were performed in quadruplicate and standard errors
calculated. In these transient transfection assays, wild-
type DNp63a strongly activated transcription of the lucif-
erase reporter through the p63 binding sites as follows:
binding site 1, to 3-fold; binding site 2, to 5-fold; binding
site 3, to 2-fold; and binding site 4, >5-fold (p ¼ 0.03
Mann-Whitney U test; Figure 3A).
To complement these findings, we knocked down Trp63
in mouse primary keratinocytes by using a pan-Trp63-
specific siRNA41 and found a statistically significant
decrease in the levels of Ripk4 transcripts (p ¼ 0.05,
Mann-Whitney U test; Figures 3B and 3C). Taken together,
the reporter and knockdown experiments strongly point
to p63, specifically the DNp63a isoform, being an activator
of RIPK4. To provide an in vivo context for these findings,72 The American Journal of Human Genetics 90, 69–75, January 13, 2we analyzed RNA extracted from the epidermis of post-
natal day 1 mice in which DNp63a overexpression is
targeted to the epidermis under the control of the bovine
keratin 5 promoter, Krt5-tTA/pTRE-DNp63a bitransgenic
mice.42 qPCR was performed with Power SYBR Green
master mix (Invitrogen) and primers defining Trp63 and
Ripk4 (Table S2) according to manufacturer’s protocol.
b-actin was used as a housekeeping gene to normalize the
amount of cDNA used. The results of these analyses
confirmed that Trp63 was upregulated 2.6-fold in
Krt5-tTA/pTRE-DNp63a mice compared to their wild-type
littermates (p ¼ 0.05, Mann-Whitney U test; Figure 3D).
Although Ripk4 expression levels were also upregulated
in the Krt5-tTA/pTRE-DNp63a bitransgenic mice, this
did not reach the threshold for significance; however,012
Figure 3. p63 Transactivates RIPK4
(A) Luciferase reporter assays demonstrate that
wild-type DNp63a strongly activates transcrip-
tion through the four binding sites (BS) located
within 56 kb of RIPK4 (*p¼ 0.03, Mann-Whitney
U test).
(B and C) siRNA knockdown of Trp63 in
mouse primary keratinocytes results in a 7-fold
reduction in Trp63 levels (p ¼ 0.02) resulting in
a more than 2-fold reduction in Ripk4 levels
(p ¼ 0.02).
(D and E) qPCR analysis of epidermis from
wild-type and mice overexpressing DNp63a
indicates that Trp63 transcripts are increased
~2.6-fold in Krt5-tTA/pTRE-DNp63a bitransgenic
mice compared to their wild-type littermates
(*p ¼ 0.05) resulting in an increase in Ripk4 tran-
scripts in DNp63a overexpressing mice compared
to their wild-type littermates. Although the
increase in Ripk4 expression levels did not reach
the threshold for significance, Pearson’s correla-
tion coefficient demonstrated an association
between the relative expression of Trp63 and
Ripk4 in Krt5-tTA/pTRE-DNp63a bitransgenic
and wild-type mice that was significant (p ¼
0.02). Regression analysis of these data confirmed
a linear relationship between increased Trp63
and Ripk4 expression levels (r2 ¼ 0.49; p ¼
0.02) (Figure S5).
Error bars indicate standard error of the mean.Pearson’s correlation coefficient demonstrated an associa-
tion between the relative expression of Trp63 and Ripk4
in Krt5-tTA/pTRE-DNp63a bitransgenic and wild-type
mice that was significant (p ¼ 0.02) (Figure 3E). Regression
analysis of these data confirmed a linear relationship
between increased Trp63 and Ripk4 expression levels
(r2 ¼ 0.49; p ¼ 0.02) (Figure S5).
The RIP kinase family is composed of a group of seven
proteins characterized by homology within their serine/
threonine kinase domain; however, each member is
defined by the unique domains linked to this region.7
RIPK4 contains an N-terminal kinase domain that displays
~40% identity with other RIP kinases attached via an
intermediate region that can be cleaved by caspases to a
C terminus containing 11 ankyrin repeats.7,43–45 Overex-
pression and inhibition studies have shown that RIPK4 isThe American Journal ofan activator of the NF-kB and JNK signaling
pathways; however, in contrast to RIPK1,
these activities can occur in a kinase-
independent manner.11,45,46 Although the
isoleucine residue at amino acid position
81, which has been shown to be mutated
to asparagine in this study (Figure 1E), has
not been directly implicated in the kinase
activity of RIPK4,46 it is highly conserved
across evolution suggesting a fundamental
role in RIPK4 function (Figure S2). Taken
together with the position of the C>A
transversion in exon 7 of RIPK4, which
results in the introduction of a homozygoustermination codon into the protein and which is therefore
predicted to result in nonsense-mediated degradation of
the mutant transcript,47 it is likely that both mutations
abrogate RIPK4 function. Support for this hypothesis is
provided by the observation that Ripk4-null mice exhibit
abnormalities of the keratinocyte proliferation-differentia-
tion switch that result in multiple epidermal adhesions
thereby phenocopying Bartsocas-Papas syndrome.9,10 It is
also notable that mice carrying loss-of-function mutations
in either Irf6, Ikka, or Sfn exhibit highly similar defects of
stratified, squamous, keratinizing epithelia suggesting
that at least a subset of these proteins function in
a common pathway with RIPK4.12–19 In this context, SFN
has been shown to be a downstream target of IKKa in
regulating the G2/M cell-cycle checkpoint in response to
DNA damage in keratinocytes; IKKa shields SFN fromHuman Genetics 90, 69–75, January 13, 2012 73
hypermethylation to prevent its silencing.48 Similarly, Irf6
and Sfn have been shown to interact epistatically, although
the molecular basis of this interaction has yet to be deter-
mined.18 Although the full extent of the interactions
between these molecules has yet to be elucidated, we
have now demonstrated that RIPK4 is a direct transcrip-
tional target of DNp63a, a protein that also activates IRF6
and IKKA,20–23 genes that are mutated in clinical condi-
tions that exhibit marked phenotypic overlap with Bartso-
cas-Papas syndrome.3,4 These observations suggest that the
transcription factor DNp63a acts as a nodal point in the
molecular events that prevent pterygium syndromes.
In summary, we report the use of whole-exome se-
quencing to demonstrate that the autosomal-recessive
disorder Bartsocas-Papas syndrome results from loss-of-
function mutations in the gene encoding receptor-inter-
acting kinase 4, an ankyrin repeat-containing kinase
essential for keratinocyte differentiation.
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